Which has better earnings and valuation, LQDA or XERS?

Xeris Biopharma has higher revenue and earnings than Liquidia. Xeris Biopharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 37.73 -$68.92M $1.37 48.72 Xeris Biopharma $291.85M 4.65 $550K -$0.11 N/A

Is LQDA or XERS more profitable?

Liquidia has a net margin of 30.74% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Liquidia's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% Xeris Biopharma -5.12% 338.21% 3.50%

Does the media favor LQDA or XERS?

In the previous week, Xeris Biopharma had 3 more articles in the media than Liquidia. MarketBeat recorded 7 mentions for Xeris Biopharma and 4 mentions for Liquidia. Liquidia's average media sentiment score of 0.99 beat Xeris Biopharma's score of 0.64 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XERS or AMRX?

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 7 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.64 beat Amneal Pharmaceuticals' score of 0.40 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DFTX or XERS?

In the previous week, Definium Therapeutics had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 12 mentions for Definium Therapeutics and 7 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.64 beat Definium Therapeutics' score of 0.41 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Xeris Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is XERS or INDV more profitable?

Indivior has a net margin of 26.65% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Xeris Biopharma -5.12% 338.21% 3.50% Indivior 26.65% -283.11% 36.85%

Does the media refer more to XERS or INDV?

In the previous week, Xeris Biopharma had 2 more articles in the media than Indivior. MarketBeat recorded 7 mentions for Xeris Biopharma and 5 mentions for Indivior. Indivior's average media sentiment score of 1.79 beat Xeris Biopharma's score of 0.64 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer MANE or XERS?

In the previous week, Xeris Biopharma had 5 more articles in the media than Veradermics. MarketBeat recorded 7 mentions for Xeris Biopharma and 2 mentions for Veradermics. Veradermics' average media sentiment score of 1.58 beat Xeris Biopharma's score of 0.64 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Xeris Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xeris Biopharma (XERS) Competitors

$7.45 -0.22 (-2.87%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$7.50 +0.05 (+0.67%)

As of 09/11/2026 07:30 PM Eastern

Compare

XERS vs. LQDA, AMRX, DFTX, INDV, and MANE

Should you buy Xeris Biopharma stock or one of its competitors? Xeris Biopharma's main competitors and comparable companies include Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Indivior (INDV), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Xeris Biopharma compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Liquidia has a net margin of 30.74% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Liquidia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Xeris Biopharma	-5.12%	338.21%	3.50%

64.5% of Liquidia shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Liquidia presently has a consensus price target of $98.08, suggesting a potential upside of 46.96%. Xeris Biopharma has a consensus price target of $12.80, suggesting a potential upside of 71.81%. Given Xeris Biopharma's higher possible upside, analysts clearly believe Xeris Biopharma is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Xeris Biopharma had 3 more articles in the media than Liquidia. MarketBeat recorded 7 mentions for Xeris Biopharma and 4 mentions for Liquidia. Liquidia's average media sentiment score of 0.99 beat Xeris Biopharma's score of 0.64 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Liquidia. Xeris Biopharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	37.73	-$68.92M	$1.37	48.72
Xeris Biopharma	$291.85M	4.65	$550K	-$0.11	N/A

Summary

Liquidia beats Xeris Biopharma on 11 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Xeris Biopharma (NASDAQ:XERS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 7 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.64 beat Amneal Pharmaceuticals' score of 0.40 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.65	$550K	-$0.11	N/A
Amneal Pharmaceuticals	$3.02B	1.80	$72.06M	$0.49	34.71

Xeris Biopharma currently has a consensus target price of $12.80, suggesting a potential upside of 71.81%. Amneal Pharmaceuticals has a consensus target price of $19.57, suggesting a potential upside of 15.06%. Given Xeris Biopharma's higher probable upside, equities analysts clearly believe Xeris Biopharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Amneal Pharmaceuticals has a net margin of 5.05% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Xeris Biopharma has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Xeris Biopharma on 11 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Xeris Biopharma has higher revenue and earnings than Definium Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Xeris Biopharma	$291.85M	4.65	$550K	-$0.11	N/A

Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Definium Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Xeris Biopharma	-5.12%	338.21%	3.50%

Definium Therapeutics currently has a consensus price target of $63.00, suggesting a potential upside of 62.00%. Xeris Biopharma has a consensus price target of $12.80, suggesting a potential upside of 71.81%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Definium Therapeutics had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 12 mentions for Definium Therapeutics and 7 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.64 beat Definium Therapeutics' score of 0.41 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Xeris Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Xeris Biopharma beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Indivior?

Xeris Biopharma (NASDAQ:XERS) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, Xeris Biopharma had 2 more articles in the media than Indivior. MarketBeat recorded 7 mentions for Xeris Biopharma and 5 mentions for Indivior. Indivior's average media sentiment score of 1.79 beat Xeris Biopharma's score of 0.64 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Xeris Biopharma has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Indivior has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Xeris Biopharma presently has a consensus price target of $12.80, suggesting a potential upside of 71.81%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 30.96%. Given Xeris Biopharma's higher probable upside, equities research analysts plainly believe Xeris Biopharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Indivior has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.65	$550K	-$0.11	N/A
Indivior	$1.24B	3.29	$210M	$2.79	12.36

Indivior has a net margin of 26.65% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Indivior	26.65%	-283.11%	36.85%

Summary

Indivior beats Xeris Biopharma on 11 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Veradermics?

Veradermics (NYSE:MANE) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

42.8% of Xeris Biopharma shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Veradermics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Xeris Biopharma	-5.12%	338.21%	3.50%

In the previous week, Xeris Biopharma had 5 more articles in the media than Veradermics. MarketBeat recorded 7 mentions for Xeris Biopharma and 2 mentions for Veradermics. Veradermics' average media sentiment score of 1.58 beat Xeris Biopharma's score of 0.64 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Xeris Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has higher revenue and earnings than Veradermics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Veradermics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Xeris Biopharma	$291.85M	4.65	$550K	-$0.11	N/A

Veradermics presently has a consensus price target of $153.00, suggesting a potential upside of 54.23%. Xeris Biopharma has a consensus price target of $12.80, suggesting a potential upside of 71.81%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Xeris Biopharma beats Veradermics on 9 of the 14 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XERS vs. The Competition

Export

Metric	Xeris Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.36B	$12.44B	$7.17B	$12.85B
Dividend Yield	N/A	2.63%	2.57%	11.71%
P/E Ratio	-67.73	799.75	274.94	25.27
Price / Sales	4.65	756.95	633.23	90.48
Price / Cash	74.37	88.17	76.65	51.52
Price / Book	93.13	10.39	10.33	6.20
Net Income	$550K	$2.85B	$3.50B	$358.50M
7 Day Performance	-12.66%	-3.61%	-3.32%	-2.35%
1 Month Performance	-12.25%	0.86%	-0.41%	-2.77%
1 Year Performance	-0.53%	3.47%	19.21%	7.63%

Xeris Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XERS Xeris Biopharma	4.1132 of 5 stars	$7.45 -2.9%	$12.80 +71.8%	-3.0%	$1.36B	$291.85M	N/A	435	Analyst Forecast Gap Up
LQDA Liquidia	3.8001 of 5 stars	$68.66 flat	$98.08 +42.9%	+147.2%	$6.15B	$158.32M	50.12	50	Analyst Downgrade
AMRX Amneal Pharmaceuticals	3.9757 of 5 stars	$17.44 flat	$19.00 +8.9%	+68.6%	$5.57B	$3.02B	35.59	8,500	Analyst Forecast
DFTX Definium Therapeutics	2.825 of 5 stars	$38.09 flat	$63.00 +65.4%	+303.0%	$5.12B	N/A	N/A	40	Analyst Forecast
INDV Indivior	4.1621 of 5 stars	$34.94 flat	$45.17 +29.3%	+44.4%	$4.12B	$1.24B	12.52	1,051	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XERS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Competitors

XERS vs. LQDA, AMRX, DFTX, INDV, and MANE

How does Xeris Biopharma compare to Liquidia?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Summary

How does Xeris Biopharma compare to Definium Therapeutics?

Summary

How does Xeris Biopharma compare to Indivior?

Summary

How does Xeris Biopharma compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Competitors

XERS vs. LQDA, AMRX, DFTX, INDV, and MANE

How does Xeris Biopharma compare to Liquidia?

Is LQDA or XERS more profitable?

Do insiders and institutionals have more ownership in LQDA or XERS?

Do analysts prefer LQDA or XERS?

Does the media favor LQDA or XERS?

Which has more risk & volatility, LQDA or XERS?

Which has better earnings and valuation, LQDA or XERS?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Do institutionals & insiders hold more shares of XERS or AMRX?

Does the media refer more to XERS or AMRX?

Which has preferable valuation & earnings, XERS or AMRX?

Do analysts recommend XERS or AMRX?

Is XERS or AMRX more profitable?

Which has more volatility and risk, XERS or AMRX?

Summary

How does Xeris Biopharma compare to Definium Therapeutics?

Which has preferable earnings and valuation, DFTX or XERS?

Which has more volatility & risk, DFTX or XERS?

Is DFTX or XERS more profitable?

Do analysts recommend DFTX or XERS?

Does the media favor DFTX or XERS?

Do institutionals and insiders have more ownership in DFTX or XERS?

Summary

How does Xeris Biopharma compare to Indivior?

Does the media refer more to XERS or INDV?

Do insiders & institutionals hold more shares of XERS or INDV?

Which has more volatility & risk, XERS or INDV?

Do analysts rate XERS or INDV?

Which has higher valuation and earnings, XERS or INDV?

Is XERS or INDV more profitable?

Summary

How does Xeris Biopharma compare to Veradermics?

Do insiders and institutionals have more ownership in MANE or XERS?

Is MANE or XERS more profitable?

Does the media prefer MANE or XERS?

Which has better valuation and earnings, MANE or XERS?

Do analysts rate MANE or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools